Article Text

Download PDFPDF
Letter response
Response to H Zeidler's comments on the INFAST study
  1. Joachim Sieper
  1. Correspondence to Professor Joachim Sieper, Medical Department I, Rheumatology, Charité Campus Benjamin Franklin, Hindenburgdamm 30, Berlin 12200, Germany; joachim.sieper{at}

Statistics from

In his comments about our Infliximab as First Line Therapy in Patients with Early Axial Spondyloarthritis (INFAST) trial,1 H Zeidler addresses the question whether a separation in patients with predominant axial spondyloarthritis (axSpA) and peripheral SpA manifestations makes sense and whether it reflects reality. Peripheral arthritis is one of the clinical parameters used in the classification criteria for axSpA.2 However, it is not used here as an activity parameter. Thus, is has been explicitly stated for these criteria that peripheral arthritis might be current or in the past. In most of the studies cited by H Zeidler peripheral arthritis1 ,3 was counted as current or in the past and current or past is not always reported in detail. However, this information is available in some of the studies. In the German Spondyloarthritis Inception Cohort (GESPIC) …

View Full Text


  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles